FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate

Benzinga2021-11-24

Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil. NRx noted that though the ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Dad123
2021-11-24
Dad123
Like and comment please
- SKLow:
  pls like,tq
Justin8991
2021-11-24
Justin8991
Ok
Trade2retire
2021-11-24
Trade2retire
[Smile]
Boonseong
2021-11-24
Boonseong
[财迷]
- Boonseong:
  [财迷]
nxw
2021-11-24
nxw
Like pls
- Dad123:
  Done
- Justin8991:
  Ok
- Dollarvan:
  Like pls
Demonsoh
2021-11-24
Demonsoh
Like please
- CuriousPhD:
  Done

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1167653292?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-24 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167653292","market":"us","top_or_hot":-1,"title":"FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate","media":"Benzinga","content":"<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">网页链接</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLFTF","symbol_name":"RELIEF THERAPEUTICS HLDG AG","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/11/24269339/fda-denies-breakthrough-tag-for-nrx-pharmas-covid-19-candidate","article_id":"1167653292","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167653292","pubTimestamp":1637762873,"columns":[],"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that th","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLFTF":"RELIEF THERAPEUTICS HLDG AG","NRXP":"NRX Pharmaceuticals Inc."},"translate_title":"美国食品和药物管理局否认NRx制药公司新冠肺炎候选人的突破性标签","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRXP":0.9,"RLFTF":0.9},"content_text":"Relief Therapeutics Holding SA's collaborating partner NRx Pharmaceuticals Inc has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.\n\nNRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.\nAdditionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.\nTherefore, the denial does not impede NRx's ability to seek drug approval.\nRelief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).\nIt is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19..\nPrice Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":874608759,"gmtCreate":1637764396437,"gmtModify":1637764396594,"author":{"id":"3581623201234305","authorId":"3581623201234305","name":"Dad123","avatar":"https://static.tigerbbs.com/ac4d85018dddfaed97e09d27a019c74f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581623201234305","authorIdStr":"3581623201234305"},"htmlText":"Like and comment please&nbsp;","listText":"Like and comment please&nbsp;","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874608759","repostId":1167653292,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6709114,"gmtCreate":1637765354197,"gmtModify":1637765354229,"authorId":3582927789816025,"author":{"id":3582927789816025,"idStr":"3582927789816025","authorId":3582927789816025,"name":"SKLow","avatar":"https://static.tigerbbs.com/b3aeaabd2ee1ec9afcdda5a4aab1994c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874608759,"type":1,"supId":0,"prevId":0,"content":"pls like,<u>tq</u>","text":"pls like,<u>tq</u>","html":"pls like,<u>tq</u>"}],"langContent":"CN"},{"id":874600536,"gmtCreate":1637764142722,"gmtModify":1637764142826,"author":{"id":"3575292984950927","authorId":"3575292984950927","name":"Justin8991","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3575292984950927","authorIdStr":"3575292984950927"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874600536","repostId":1167653292,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874871433,"gmtCreate":1637763290725,"gmtModify":1637763290856,"author":{"id":"3576159555258706","authorId":"3576159555258706","name":"Trade2retire","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":8,"crmLevelSwitch":0,"idStr":"3576159555258706","authorIdStr":"3576159555258706"},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874871433","repostId":1167653292,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874871540,"gmtCreate":1637763288623,"gmtModify":1637763288762,"author":{"id":"3585729801280242","authorId":"3585729801280242","name":"Boonseong","avatar":"https://static.tigerbbs.com/246facebf009ccbd87b47e3e304c37ef","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585729801280242","authorIdStr":"3585729801280242"},"htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874871540","repostId":1167653292,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6708509,"gmtCreate":1637763302491,"gmtModify":1637763302580,"authorId":3585729801280242,"author":{"id":3585729801280242,"idStr":"3585729801280242","authorId":3585729801280242,"name":"Boonseong","avatar":"https://static.tigerbbs.com/246facebf009ccbd87b47e3e304c37ef","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874871540,"type":1,"supId":0,"prevId":0,"content":"[财迷]","text":"[财迷]","html":"[财迷]"}],"langContent":"CN"},{"id":874871358,"gmtCreate":1637763260314,"gmtModify":1637763260539,"author":{"id":"3555755639757611","authorId":"3555755639757611","name":"nxw","avatar":"https://static.tigerbbs.com/0a3041e78835567c8db5934504534a17","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3555755639757611","authorIdStr":"3555755639757611"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/874871358","repostId":1167653292,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6708790,"gmtCreate":1637764407348,"gmtModify":1637764407382,"authorId":3581623201234305,"author":{"id":3581623201234305,"idStr":"3581623201234305","authorId":3581623201234305,"name":"Dad123","avatar":"https://static.tigerbbs.com/ac4d85018dddfaed97e09d27a019c74f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874871358,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":6708729,"gmtCreate":1637764190682,"gmtModify":1637764190769,"authorId":3575292984950927,"author":{"id":3575292984950927,"idStr":"3575292984950927","authorId":3575292984950927,"name":"Justin8991","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874871358,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6708591,"gmtCreate":1637763563033,"gmtModify":1637763563062,"authorId":3555014251535651,"author":{"id":3555014251535651,"idStr":"3555014251535651","authorId":3555014251535651,"name":"Dollarvan","avatar":"https://static.tigerbbs.com/0316ab12b442ee2cd79936de06de5089","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874871358,"type":1,"supId":0,"prevId":0,"content":"Like pls","text":"Like pls","html":"Like pls"}],"langContent":"CN"},{"id":874873453,"gmtCreate":1637763222850,"gmtModify":1637763222930,"author":{"id":"3586616403399133","authorId":"3586616403399133","name":"Demonsoh","avatar":"https://static.tigerbbs.com/bfc41482583c4b0bdc313eb042de776e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586616403399133","authorIdStr":"3586616403399133"},"htmlText":"Like please&nbsp;","listText":"Like please&nbsp;","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874873453","repostId":1167653292,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6708726,"gmtCreate":1637764161801,"gmtModify":1637764161895,"authorId":3581629167637532,"author":{"id":3581629167637532,"idStr":"3581629167637532","authorId":3581629167637532,"name":"CuriousPhD","avatar":"https://static.tigerbbs.com/6f2eb06a7bbc1da3f700038e46d4e807","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874873453,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":48,"commentSize":11,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167653292"}